Philippines - English - FDA (Food And Drug Administration)

fresenius kabi philippines, inc. - hydroxyethyl starch (130/0.4) , electrolytes - solution for iv infusion - 6% w/v

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - propofol - emulsion for inj/inf - 1 %w/v - other general anesthetics

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - propofol - emulsion for inj/inf - 2 %w/v - other general anesthetics

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - propofol - emulsion for inj/inf - 1 %w/v - other general anesthetics

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - propofol - emulsion for injection/infusion - 2 percent - other general anesthetics; propofol

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - fentanyl citrate -

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - glucose monohydrate 55 g/l;   - solution for infusion - 5 % - active: glucose monohydrate 55 g/l   excipient: hydrochloric acid sodium hydroxide water for injection

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - dexmedetomidine hydrochloride, quantity: 236 microgram (equivalent: dexmedetomidine, qty microgram) - injection, concentrated - excipient ingredients: sodium chloride; water for injections - icu sedation: for sedation of initially intubated patients during treatment in an intensive care setting. the use of dexmedetomidine fresenius by continuous infusion in these patients should not exceed 24 hours. procedural sedation: for sedation of non-intubated patients prior to and/or during surgical and other procedures.

European Union - English - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - bortezomib - multiple myeloma - antineoplastic agents - bortezomib as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.bortezomib in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.

Zimbabwe - English - Medicines Control Authority

fresenius kabi south africa (pty) ltd - propofol - emulsions; injectable - 10mg/ml